Your browser doesn't support javascript.
loading
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson, Paul G; Perrot, Aurore; San-Miguel, Jesus; Beksac, Meral; Spicka, Ivan; Leleu, Xavier; Schjesvold, Fredrik; Moreau, Philippe; Dimopoulos, Meletios A; Huang, Jeffrey Shang-Yi; Minarik, Jiri; Cavo, Michele; Prince, H Miles; Malinge, Laure; Dubin, Franck; van de Velde, Helgi; Anderson, Kenneth C.
Affiliation
  • Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu.
  • Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
  • San-Miguel J; Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain.
  • Beksac M; Department of Hematology, Ankara University, Ankara, Turkey.
  • Spicka I; General Faculty Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France.
  • Schjesvold F; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Moreau P; Hematology Department, CHU Nantes, Nantes, France.
  • Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Huang JS; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
  • Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
  • Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Prince HM; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia.
  • Malinge L; Sanofi R&D, Vitry, France.
  • Dubin F; Sanofi R&D, Vitry, France.
  • van de Velde H; Sanofi R&D, Vitry, France.
  • Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lancet Oncol ; 23(3): 416-427, 2022 03.
Article in En | MEDLINE | ID: mdl-35151415
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Myeloma Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Humans Language: En Year: 2022 Type: Article